Recruiting

Lidocaine

Sponsor:

Oregon Health and Science University

Code:

NCT06121466

Conditions

Anterior Cutaneous Nerve Entrapment Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Abdominal wall injections with lidocaine 2%

Study Details

Brief summary:

This is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. Subjects will be recruited at the outpatient gastroenterology clinic at OHSU.

Conditions

Anterior Cutaneous Nerve Entrapment Syndrome

Study ID

NCT06121466

Start date

Jan 1, 2023

Status verified date

Aug, 2025

Completion date

Dec, 2025

Anticipated

Primary completion date

Dec, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Localized abdominal wall pain
  • Average daily pain (7-day recall) ≥ 3 on a scale of 0-10
  • Suspected abdominal wall etiology for abdominal pain
  • Positive Carnett's sign or pain near an incisional site
  • 18 years of age or older

Exclusion Criteria:

  • Suspected visceral etiology for the abdominal pain
  • Severe allergy to lidocaine
  • Unwillingness or inability to provide informed consent
  • Low probability of follow-up
  • Abdominal wall hernia noted at the point of pain
  • History of trigger point injections for abdominal pain
  • Bleeding disorder
  • Pregnancy, incarceration or decisionally impaired

Study Design

Enrollment

45 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Abdominal wall injections for abdominal wall pain

Patients with abdominal pain who are suspected of having abdominal wall pain.

Interventions

Abdominal wall injections with lidocaine 2%

Injections will be administered for patient who are identified as having abdominal wall pain.

Primary outcome measure

  • 1) To measure the change in abdominal wall pain 1-week, 1-month and 3-months following abdominal wall injections, with improvement defined as a 50% reduction in baseline pain score measured using an 11-point numeric scale. [ Time Frame: 12 weeks ]
  • 2) To determine patient characteristics, such as pain catastrophizing, associated with a response to abdominal wall injection [ Time Frame: 12 weeks ]
  • 2) To determine patient characteristics, such as patient reported functional status, pain status, and global estimate status; associated with a response to abdominal wall injection [ Time Frame: 12 weeks ]
  • 2) To determine patient characteristics, within seven health domains, associated with a response to abdominal wall injection [ Time Frame: 12 weeks ]
  • 2) To determine patient characteristics, such as psychological inflexibility, associated with a response to abdominal wall injection [ Time Frame: 12 weeks ]
  • 3) To determine the rate of adverse events associated with abdominal wall injection. [ Time Frame: 12 weeks ]
  • 4) To measure pain thresholds with use of heat, using quantitative sensory testing (QST) in patients receiving abdominal wall injections. [ Time Frame: 12 weeks ]
  • 4) To measure pain thresholds with use of temporal summation, using quantitative sensory testing (QST) in patients receiving abdominal wall injections. [ Time Frame: 12 weeks ]
  • 4) To measure pain thresholds with use of pressure thresholds, using quantitative sensory testing (QST) in patients receiving abdominal wall injections. [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Sophia Lichenstein-Hill, DNP

5038801235lichenst@ohsu.edu

Locations

OHSU

Recruiting

Portland, Oregon, United States, 97239

Contacts

Sophia Lichenstein-Hill

5034944373lichenst@ohsu.edu

Oregon Health Sciences University

Recruiting

Portland, Oregon, United States, 97239

Contacts

Oregon HS University

5034944373lichenst@ohsu.edu

More Information

Sponsor

Oregon Health and Science University

Last update posted

Sep 2, 2025

Last verified

Aug, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Oregon Health and Science University on 2025-09-02.